Dogwood Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Dogwood Therapeutics, Inc. (DWTX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$4.78 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-08-14
- Dogwood Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2026-06-30 was -$4.78M.
- Dogwood Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2026-03-31 was -$4.88M.
- Dogwood Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2025-09-30 was -$15.33M.
- Dogwood Therapeutics, Inc. income (loss) from continuing operations before income taxes, domestic for the quarter ending 2025-06-30 was -$3.05M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 3 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 9 month |
|---|---|---|---|
| 2026-06-30 | -$4.78M 10-Q · filed 2026-08-14 | -$9.66M 10-Q · filed 2026-08-14 | |
| 2026-03-31 | -$4.88M 10-Q · filed 2026-05-15 | ||
| 2025-09-30 | -$15.33M 10-Q · filed 2025-11-07 | -$18.38M derived: sum of 2 quarters · filed 2026-08-14 | -$28.70M 10-Q · filed 2025-11-07 |
| 2025-06-30 | -$3.05M 10-Q · filed 2026-08-14 | -$13.38M 10-Q · filed 2026-08-14 | |
| 2025-03-31 | -$10.33M 10-Q · filed 2026-05-15 | ||
| 2024-09-30 | -$2.28M 10-Q · filed 2025-11-07 | -$3.33M derived: sum of 2 quarters · filed 2025-11-07 | -$4.62M 10-Q · filed 2025-11-07 |
| 2024-06-30 | -$1.05M 10-Q · filed 2025-08-13 | -$2.34M 10-Q · filed 2025-08-13 | |
| 2024-03-31 | -$1.29M 10-Q · filed 2025-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |